These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30413113)

  • 1. A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice.
    Swenson S; Minea RO; Tuan CD; Thein TZ; Chen TC; Markland FS
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30413113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review.
    Schönthal AH; Swenson SD; Chen TC; Markland FS
    Biochem Pharmacol; 2020 Nov; 181():114149. PubMed ID: 32663453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods for Evaluation of a Snake Venom-Derived Disintegrin in Animal Models of Human Cancer.
    Swenson SD; Silva-Hirschberg C; Markland FS
    Methods Mol Biol; 2020; 2068():185-204. PubMed ID: 31576529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
    Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
    Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential.
    Minea R; Helchowski C; Rubino B; Brodmann K; Swenson S; Markland F
    Toxicon; 2012 Mar; 59(4):472-86. PubMed ID: 21354198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of Vipera Anatolica Venom Disintegrin via Intracellular Uptake with Radiolabeling Study and Cell-Based Electrochemical Biosensing Assay.
    Er O; Eksin E; Soylu HM; Göçmen B; Nalbantsoy A; Yurt F; Erdem A
    Appl Biochem Biotechnol; 2019 Apr; 187(4):1539-1550. PubMed ID: 30276529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
    Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
    Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression.
    Swenson S; Costa F; Minea R; Sherwin RP; Ernst W; Fujii G; Yang D; Markland FS
    Mol Cancer Ther; 2004 Apr; 3(4):499-511. PubMed ID: 15078994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
    Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
    Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
    Scaringi C; Minniti G; Caporello P; Enrici RM
    Anticancer Res; 2012 Oct; 32(10):4213-23. PubMed ID: 23060541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of radiolabeled methyl N-[5-(3'-halobenzoyl)-1H-benzimidazol-2-yl]carbamate for cancer radiotherapy.
    Kortylewicz ZP; Coulter DW; Baranowska-Kortylewicz J
    Drug Dev Res; 2020 Feb; 81(1):62-69. PubMed ID: 31593323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of snake venom disintegrins by positive Darwinian selection.
    Juárez P; Comas I; González-Candelas F; Calvete JJ
    Mol Biol Evol; 2008 Nov; 25(11):2391-407. PubMed ID: 18701431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Brain Tumor Radiotherapy Using an Auger Emitter.
    Pirovano G; Jannetti SA; Carter LM; Sadique A; Kossatz S; Guru N; Demétrio De Souza França P; Maeda M; Zeglis BM; Lewis JS; Humm JL; Reiner T
    Clin Cancer Res; 2020 Jun; 26(12):2871-2881. PubMed ID: 32066626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
    van Nifterik KA; van den Berg J; Stalpers LJ; Lafleur MV; Leenstra S; Slotman BJ; Hulsebos TJ; Sminia P
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1246-53. PubMed ID: 17967314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.